Superdisintegrants Market

Superdisintegrants Market Size (2023 to 2028)

As per our research report, the size of the global superdisintegrants market is projected to reach USD 386.3 Million in 2023. This value is estimated to grow at a CAGR of 7.8% during the forecast period and be worth USD 562.4 Million by 2028.

Superdisintegrants Market Share Insights:

• Based on product type, the crospovidone segment is anticipated to register the lead in the market in the coming years.
• Based on application, the capsules segment led the market in 2022.
• Based on the therapeutic area, the gastrointestinal segment accounted for the major share of the market in 2022.
• North America had the largest market share of the global market in 2022.

Superdisintegrants are one of the many excipients utilized in the pharmaceutical industry for tablet-based drug administration. Disintegrants are substances that expand and dissolve when wet causing the tablet to break apart in the digestive tract, releasing active ingredients for absorption. In addition, they make sure that when the tablet is in contact with water, it breaks down rapidly into smaller fragments, making way for dissolution, thus reducing the time required for the drug release.

MARKET DRIVERS:

Increasing healthcare expenditure and healthcare awareness among individuals have accounted for the growth of the global superdisintegrants market.

Worldwide healthcare expenditure is growing continuously, and the trend is anticipated to grow in the coming years. The rising aging population, growing chronic disease patient count, and increasing costs of medical technologies are contributing to the growing healthcare expenditure worldwide. According to statistics published by the World Health Organization (WHO), worldwide healthcare expenditure was valued at USD 6.5 Trillion in 2010 and increased to USD 9.7 Trillion in 2019. The developed countries accounted for the major proportion of global healthcare spending. On the other hand, healthcare spending from developing and underdeveloped countries is also increasing as they seek better healthcare access and increasing the burden of various diseases. The growing healthcare expenditure results in the growing consumption of superdisintegrants and boosting the market’s growth rate.

The growth of the global superdisintegrants market is further attributed to factors such as the growing population of geriatric and pediatric patients, the growing generic drugs market, and the development of new superdisintegrants in the pharmaceutical industry. In addition, increasing demand for manufacturing highly accurate and useful drugs with appropriate dosage levels of various excipients and active ingredients elevates the market's growth rate. Furthermore, the growing healthcare expenditure and increasing disposable income in urban areas are further propelling the superdisintegrants market growth.

The main goal of drug manufacturers is to reduce the dissolving time of a tablet in the digestive part and release active ingredients, which is solely to set up growth opportunities for the market. The growing prevalence of producing generic drugs is also fuelling the market's growth. In addition, rising incidences of chronic diseases and other health disorders due to lifestyle changes and food habits create chances for the market to grow eventually.

MARKET RESTRAINTS:

However, the declining financial support for R&D fields hinders the market's growth. Although synthetic Superdisintegrants have been the standard for many decades, more significant research into natural Superdisintegrants will motivate the future growth of the global superdisintegrants market.

Impact of Covid-19 on the global superdisintegrants Market:

The COVID-19 pandemic has disrupted the global economy. It is due to the commercial and industrial zones have been put under lockdown by government bodies. However, if no more lockdowns are enforced worldwide, the economy is expected to rebound quickly and return to pre-COVID levels by the end of 2021. Pharmaceutical and biotech companies collaborate with governments worldwide to combat the COVID-19 epidemic, from vaccine production to preparing for pharmaceutical supply chain challenges.

Besides that, widely used medications like Hydroxychloroquine have seen a significant rise in demand for the treatment of COVID-19. Since many developing countries are low on these medications, the high demand has presented a tremendous opportunity for manufacturers of COVID-19 control drugs. Superdisintegrants are agents added to tablets to speed up the tablet's breakdown into small fragments in aqueous conditions, allowing the substance to be released more quickly into the body. The global effects of the COVID-19 pandemic are already being felt, and the superdisintegrants market will be significantly impacted in 2020. Superdisintegrants have gained the attention of the pharmaceutical industry in recent years because they improve the solubility of active pharmaceutical ingredients (API) in the body by increasing drug absorption, thus increasing drug bioavailability. Tablets and capsules contain the super disintegrant agent. Therefore, the market for superdisintegrants has been steadily growing in recent years, and it is expected to continue growing during the forecast period.

REPORT COVERAGE:

This research report on the global superdisintegrants market has been segmented and sub-segmented based on the product type, application, therapeutic area & region.

Superdisintegrants Market – By Product Type: 

• Natural Superdisintegrants
• Synthetic Superdisintegrants
  • Modified Starch
  • Crospovidone
  • Modified Cellulose
  • Ion Exchange Resins
  • Calcium Silicates
• Others

Based on product, the natural superdisintegrants segment is predicted to have the highest CAGR during the forecast period owing to the increasing prevalence of organic raw materials to manufacture various drugs that configure lower side effects.

However, the synthetic superdisintegrants segment had the largest share of the global market in 2022 and is expected to showcase healthy occupancy in the market in the coming years. Furthermore, under the sub-segments, the crospovidone segment is anticipated to showcase a healthy CAGR during the forecast period.

Superdisintegrants Market – By Application:

• Capsules
• Tablets

Based on the application, the capsules segment is projected to witness a major share of the global superdisintegrants market in 2022, and the domination of the segment is likely to continue during the forecast period due to the increasing production rate of the drugs to meet the end-users requirements.

Superdisintegrants Market – By Therapeutic Area:

• Gastrointestinal diseases
• Neurological diseases
• Oncology
• Infectious Diseases
• Cardiovascular Diseases
• Hematological diseases
• Inflammatory Diseases

Based on the therapeutic area, the gastrointestinal diseases segment is expected to lead the market during the forecast period. The growing popularity of over-the-counter drugs and the rise in the support from private and public organizations through investments mainly to improve the quality of treatment procedures is leveraging the segment's growth rate. Superdisintegrants are used to treat various gastrointestinal diseases such as gastrointestinal diseases, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and gastroesophageal reflux disease (GERD). Croscarmellose sodium, crospovidone, sodium starch glycolate, and pregelatinized starch are some of the most common superdisintegrants used to treat GI diseases.

Superdisintegrants Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Geographically, the North American superdisintegrants market led the market in 2022, and the domination of the North American region is anticipated to continue throughout the forecast period. Increasing financial support for developing innovative oral dosage forms and constant effort devoted to providing superior quality and compliant products in the market are the primary factors responsible for the dominance of North America. In addition, the growing adoption of oral dosage forms such as tablets and capsules and the increasing demand for technological advancements such as drug delivery is forecasted to result in regional market growth. Countries such as the United States and Canada contribute significantly to the North American market growth.

The Europe superdisintegrants market held a substantial global market share in 2022. The EU market is expected to register a healthy CAGR during the forecast period. The growing investments and increasing R&D efforts from the market participants are predicted to result in the growth of the European market. Countries such as UK and Germany are expected to account for a major share of the European market in the coming years.

The Asia Pacific superdisintegrants market is expected to grow the fastest due to increasing healthcare spending, rising healthcare infrastructure and awareness, and growing outsourcing of excipient manufacturing to Asian countries like India and China. The synthetic superdisintegrants market segment held the largest share of the global superdisintegrants market. It mainly accounts for the prevalent use of excipients such as sodium starch glycolate and crospovidone in oral and fast-disintegrating tablets. Rising incidences of cardiovascular diseases, neurological diseases, and other related diseases are expected to drive the demand for fast-disintegrating tablets, driving the market of Superdisintegrants during the forecast period.

The Latin America superdisintegrants market is expected to register a healthy CAGR during the forecast period.

The superdisintegrants market in MEA is forecasted to showcase a moderate CAGR in the coming years.

KEY MARKET PLAYERS:

Companies playing a promising role in the global superdisintegrants market and profiled in this report are Ashland, BASF SE, FMC Corporation, JRS Pharma, DFE Pharma, Roquette, The Dow Chemical Company, Asahi Kasei Corporation, Nippon Soda Co, Huber Corporation.

RECENT MARKET DEVELOPMENTS:

• In October 2019, Roquette opened a new Pharmaceutical Research and Development (R&D) and Customer Technical Service (CTS) facility in Biopolis, Singapore, to develop new drugs and applications for existing products and preclinical research.
• In March 2017, BASF Group launched the Innovation Campus, Asia Pacific, in India, marking its most significant R&D investment. The organization invested USD 61.6 million (EUR 50 million) in this center to expand its global and regional research activities.
• In October 2016, Ashland opened a new pharmaceutical excipient facility in Nanjing, China. Through this facility, the company offers highly functional excipient technologies to manufacturers of oral pharmaceuticals and custom formulation solutions.
• In June 2016, DuPont established its ASEAN (Association of Southeast Asian Nations) headquarters in Singapore to strengthen its competitive position in major growth markets.
• In March 2016, Roquette was awarded the EXCiPACT certification for Good Industrial Practices, including the manufacturing, testing, and packaging a range of excipients.